| P2093 | author name string | Michel Cyr | |
| | Manon Lebel | |
| | Pierre Robinson | |
| P2860 | cites work | Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP | Q22008544 |
| | Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons | Q22010952 |
| | Phosphorylation of protein phosphatase inhibitor-1 by Cdk5 | Q24091381 |
| | Dopamine D5 receptors of rat and human brain | Q24290422 |
| | Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter | Q24310836 |
| | Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1 | Q24313045 |
| | Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine | Q24319813 |
| | Dopamine receptors: from structure to function | Q24336139 |
| | Multiple human D5 dopamine receptor genes: a functional receptor and two pseudogenes | Q24560472 |
| | Expression cloning of a reserpine-sensitive vesicular monoamine transporter | Q24563187 |
| | Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin | Q24564132 |
| | Increased baseline occupancy of D2 receptors by dopamine in schizophrenia | Q24676113 |
| | Coupling of dopamine receptor subtypes to multiple and diverse G proteins | Q28138148 |
| | Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration | Q28140796 |
| | Amplification of dopaminergic signaling by a positive feedback loop | Q28142174 |
| | Signal transduction by the JNK group of MAP kinases | Q28142592 |
| | Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain | Q28276882 |
| | Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity | Q28325787 |
| | In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen | Q28340224 |
| | Profound neuronal plasticity in response to inactivation of the dopamine transporter | Q28508907 |
| | Cocaine-induced proliferation of dendritic spines in nucleus accumbens is dependent on the activity of cyclin-dependent kinase-5 | Q28568627 |
| | Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32 | Q28570233 |
| | Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex | Q28575970 |
| | Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor | Q28577705 |
| | Selective up-regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation | Q28577907 |
| | A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter | Q28581165 |
| | Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors | Q28582006 |
| | Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice | Q28592746 |
| | cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway | Q28611450 |
| | Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases | Q29614338 |
| | D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons | Q29615480 |
| | Dopamine transporter knock-out mice are hypersensitive to 3-nitropropionic acid-induced striatal damage. | Q42523227 |
| | Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. | Q42541545 |
| | Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum | Q42555260 |
| | PKA phosphorylation of Src mediates cAMP's inhibition of cell growth via Rap1. | Q42819518 |
| | Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine | Q43509401 |
| | D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. | Q43513203 |
| | Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. | Q43553698 |
| | Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells | Q43572866 |
| | Factors associated with slow progression in Huntington's disease | Q43593771 |
| | Increased expression of the transcription factor E2F1 during dopamine-evoked, caspase-3-mediated apoptosis in rat cortical neurons | Q43640154 |
| | Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases | Q43681031 |
| | Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. | Q43683702 |
| | Elevated levels of ΔFosB and RGS9 in striatum in Parkinson’s disease | Q43807399 |
| | Dopamine D2 receptors are present in prefrontal cortical afferents and their targets in patches of the rat caudate-putamen nucleus | Q43856112 |
| | D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. | Q44037073 |
| | Protection of striatal neurons by joint blockade of D1 and D2 receptor subtypes in an in vitro model of cerebral hypoxia | Q44046947 |
| | D1 dopamine receptor regulation of microtubule-associated protein-2 phosphorylation in developing cerebral cortical neurons. | Q44067022 |
| | Tetrabenazine treatment for Huntington's disease-associated chorea | Q44240628 |
| | Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. | Q44345639 |
| | Chronic Stimulation of D1 Dopamine Receptors in Human SK-N-MC Neuroblastoma Cells Induces Nitric-oxide Synthase Activation and Cytotoxicity | Q44435271 |
| | Cyclin-dependent kinase 5 phosphorylates the N-terminal domain of the postsynaptic density protein PSD-95 in neurons. | Q44746561 |
| | Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors. | Q44755344 |
| | Striatal protection induced by lesioning the substantia nigra of rats subjected to focal ischemia | Q44807649 |
| | Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain | Q45064174 |
| | Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. | Q45130529 |
| | L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain | Q45248364 |
| | Functional decline in Huntington's disease | Q45288490 |
| | Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease | Q45289366 |
| | Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. | Q45296651 |
| | Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. | Q45296860 |
| | Neuropathological classification of Huntington's disease | Q45297167 |
| | Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial | Q45300094 |
| | Predictive test for Huntington's chorea | Q45300600 |
| | Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin | Q45302968 |
| | Attitudes of Those at Risk for Huntington's Disease toward Presymptomatic Provocative Testing | Q45304364 |
| | Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease | Q45310306 |
| | Dopaminergic Modulation of NMDA-Induced Whole Cell Currents in Neostriatal Neurons in Slices: Contribution of Calcium Conductances | Q46110140 |
| | Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism | Q46493228 |
| | ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice | Q46684571 |
| | Dopamine and N-Methyl-D- Aspartate Receptor Interactions in the Neostriatum | Q46717751 |
| | Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats | Q46778385 |
| | A brain-specific activator of cyclin-dependent kinase 5. | Q48079027 |
| | Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation | Q48127716 |
| | Intrastriatal dopamine injection induces apoptosis through oxidation-involved activation of transcription factors AP-1 and NF-kappaB in rats | Q48153535 |
| | The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra | Q48245002 |
| | The involvement of p53 in dopamine-induced apoptosis of cerebellar granule neurons and leukemic cells overexpressing p53. | Q48261311 |
| | Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits | Q48271271 |
| | 6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions | Q48313514 |
| | Dopamine D3 receptor mRNA and binding sites in human brain | Q48316464 |
| | Modeling dopamine system dysfunction in experimental animals | Q48323335 |
| | DeltaFosB: a molecular switch for long-term adaptation in the brain | Q35974744 |
| | Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. | Q35978877 |
| | Is levodopa toxic? | Q36022114 |
| | Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa | Q36085612 |
| | The role of D1 dopamine receptors and phospho-ERK in mediating cytotoxicity. Commentary | Q36129326 |
| | Ion channels in cell proliferation and apoptotic cell death | Q36345950 |
| | Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it? | Q36380359 |
| | Tetrabenazine in the treatment of hyperkinetic movement disorders | Q36390838 |
| | Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter | Q36448717 |
| | Expression of the Immediate Early Gene c-fos in Basal Ganglia: Induction by Dopaminergic Drugs | Q36527086 |
| | Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies | Q36558137 |
| | D1 and D2 dopamine receptor mRNA in rat brain | Q37419023 |
| | Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections | Q37706532 |
| | Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways | Q38302233 |
| | A transitory activation of protein kinase-A induces a sustained tau hyperphosphorylation at multiple sites in N2a cells-imply a new mechanism in Alzheimer pathology | Q40319166 |
| | Dopamine receptors: molecular biology, biochemistry and behavioural aspects | Q40604994 |
| | Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors. | Q40662659 |
| | Secondary Excitotoxicity Contributes to Dopamine-Induced Apoptosis of Dopaminergic Neuronal Cultures | Q41016575 |
| | Molecular physiology and regulation of catecholamine transporters. | Q41084438 |
| | Dopamine receptors and brain function. | Q41345716 |
| | MPP+-induced increases in extracellular potassium ion activity in rat striatal slices suggest that consequences of MPP+ neurotoxicity are spread beyond dopaminergic terminals | Q41425239 |
| | Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum | Q41922304 |
| | Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity | Q42145267 |
| | Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. | Q42455499 |
| | Bimodal induction of dopamine-mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autoxidation | Q42457188 |
| | Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions. | Q42461604 |
| | Dopamine receptor-mediated Ca(2+) signaling in striatal medium spiny neurons | Q42465714 |
| | Magnetic resonance imaging at microscopic resolution reveals subtle morphological changes in a mouse model of dopaminergic hyperfunction. | Q42477579 |
| | Age-associated impairment in brain MAPK signal pathways and the effect of caloric restriction in Fischer 344 rats | Q42482755 |
| | Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons | Q42484453 |
| | Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy | Q42517911 |
| | Molecular basis of long-term plasticity underlying addiction | Q29620539 |
| | Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. | Q30432694 |
| | Hyperactivity and impaired response habituation in hyperdopaminergic mice | Q30496538 |
| | Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. | Q30886204 |
| | Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration | Q30992818 |
| | Persistent changes in striatal gene expression induced by long‐term l‐DOPA treatment in a rat model of Parkinson's disease | Q31027552 |
| | Antipsychotic treatment induces alterations in dendrite- and spine-associated proteins in dopamine-rich areas of the primate cerebral cortex | Q31864319 |
| | Cytotoxic and genotoxic potential of dopamine | Q33603762 |
| | Treating and preventing levodopa-induced dyskinesias: current and future strategies | Q33688757 |
| | Functional hyperdopaminergia in dopamine transporter knock-out mice | Q33704177 |
| | Dopamine transporters and neuronal injury | Q33739406 |
| | Structure and function of dopamine receptors | Q33828020 |
| | Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation | Q33922831 |
| | The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. | Q33930416 |
| | Neuronal cell death in Huntington's disease: a potential role for dopamine | Q33934225 |
| | Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. | Q33961999 |
| | Dopamine receptors: from structure to behavior | Q34070870 |
| | A decade of CDK5. | Q34093501 |
| | Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes | Q34142470 |
| | Limitations of current Parkinson's disease therapy | Q34187123 |
| | Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis | Q34200326 |
| | Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles | Q34279396 |
| | Pathophysiology of levodopa-induced dyskinesia: potential for new therapies | Q34325365 |
| | D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade | Q34332622 |
| | Dopamine receptor signaling | Q34364279 |
| | Dopamine D1 receptors mediate CREB phosphorylation via phosphorylation of the NMDA receptor at Ser897-NR1. | Q34372253 |
| | Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons | Q34415141 |
| | What has been learnt from study of dopamine receptors in Parkinson's disease? | Q34491517 |
| | Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. | Q34543496 |
| | Antipsychotic Drug-Induced Movement Disorders | Q35105771 |
| | Cyclin-dependent kinase-5 in neurodegeneration. | Q35686119 |
| | Oxygen radicals as key mediators in neurological disease: fact or fiction? | Q35753839 |
| | Levodopa in the treatment of Parkinson's disease: current controversies | Q35889917 |
| | Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain | Q35904983 |
| | A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. | Q48329693 |
| | Autoradiographic localization and quantification of dopamine D2 receptors in normal human brain with [3H]N-n-propylnorapomorphine | Q48334200 |
| | Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration | Q48345238 |
| | Dopaminergic modulation of early signs of excitotoxicity in visualized rat neostriatal neurons | Q48345597 |
| | Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection | Q48360517 |
| | Intrastriatal injection of dopamine results in DNA damage and apoptosis in rats | Q48403601 |
| | Nerve terminal damage in cerebral ischemia: protective effect of alpha-methyl-para-tyrosine | Q48460032 |
| | Bidirectional regulation of DARPP-32 phosphorylation by dopamine. | Q48617260 |
| | Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. | Q48631699 |
| | Dopaminergic modulation of excitotoxicity in rat striatum: Evidence from nigrostriatal lesions | Q48684285 |
| | Dopamine-glutamate interactions in the striatum: behaviourally relevant modification of excitotoxicity by dopamine receptor-mediated mechanisms | Q48855715 |
| | Atypical and typical neuroleptic treatments induce distinct programs of transcription factor expression in the striatum | Q48892221 |
| | Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. | Q48957628 |
| | Genetic toxicity of dopamine | Q50210563 |
| | Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory | Q50951137 |
| | Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats | Q51759517 |
| | D1 and D2 dopamine receptor function in the striatum: coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons. | Q52012047 |
| | Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. | Q52017802 |
| | PKA phosphorylations on tau: developmental studies in the mouse | Q52165669 |
| | Expression of the D3 dopamine receptor in peptidergic neurons of the nucleus accumbens: comparison with the D1 and D2 dopamine receptors. | Q55066633 |
| | Coordinated Expression of Dopamine Receptors in Neostriatal Medium Spiny Neurons | Q56568482 |
| | Toxicity of Dopamine to Striatal Neurons In Vitro and Potentiation of Cell Death by a Mitochondrial Inhibitor | Q59393050 |
| | D1 and D2 dopamine receptor gene expression in the rat striatum: Sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAS in distinct neuronal populations of the dorsal and ventral striatum | Q61762612 |
| | Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity | Q63256021 |
| | L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset | Q64767857 |
| | Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration | Q64782355 |
| | Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum | Q64789945 |
| | Loss of striatal neurons in Parkinson's disease: a cytometric study | Q64809068 |
| | Regional study of 3H-spiperone binding and the dopamine-sensitive adenylate cyclase in rat brain | Q66923497 |
| | Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat | Q67209822 |
| | In vivo trapping of hydroxyl free radicals in the striatum utilizing intracranial microdialysis perfusion of salicylate: effects of MPTP, MPDP+, and MPP+ | Q67505470 |
| | Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease | Q68502274 |
| | Excitotoxicity of NMDA and kainic acid is modulated by nigrostriatal dopaminergic fibres | Q69268468 |
| | Autoradiographic localization of D1 and D2 dopamine receptors in the human brain | Q70063820 |
| | Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates | Q71482505 |
| | Identification of catechol-protein conjugates in neostriatal slices incubated with [3H]dopamine: impact of ascorbic acid and glutathione | Q72109104 |
| | Enzymatic oxidation of dopamine: the role of prostaglandin H synthase | Q72429983 |
| | Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease | Q72798594 |
| | Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death | Q73123591 |
| | D1 dopamine receptor-induced cyclic AMP-dependent protein kinase phosphorylation and potentiation of striatal glutamate receptors | Q73229632 |
| | Dopamine D(5) receptor immunolocalization in rat and monkey brain | Q73955612 |
| | Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence | Q74746919 |
| | Huntington's Disease | Q82993834 |
| P433 | issue | 1 | |
| P921 | main subject | neurodegeneration | Q1755122 |
| P304 | page(s) | 18-29 | |
| P577 | publication date | 2007-02-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Canadian Journal of Neurological Sciences | Q5030246 |
| P1476 | title | Canadian Association of Neurosciences Review: the role of dopamine receptor function in neurodegenerative diseases | |
| P478 | volume | 34 | |